Moderna COVID-19 vaccine 2.0: Lower dose, fewer side effects

The company expects to be offering different dose levels in 2022.

The Moderna COVID-19 vaccine received an emergency use authorization from the FDA in December 2020, but the biotech company has continued to develop the shot — and it expects the next version to produce fewer side effects.

The challenge: The Moderna COVID-19 vaccine is a marvel of modern medicine — the result of decades of research and development on mRNA vaccines. Just six weeks after the novel coronavirus’s genome was first sequenced, Moderna was able to have a vaccine candidate ready for testing, and after proving incredibly effective in trials, it was authorized for use less than a year later.

That efficacy has held up in the real world, too — the shot has helped slash case numbers in places where it’s been widely deployed — but there’s still room for improvement.

The Moderna COVID-19 vaccine is the same type of shot as Pfizer’s authorized vaccine, but people who receive it report more side effects. The reason for that is pretty straightforward: each Moderna dose contains more than three times the amount of vaccine.

Going with a high dose out the gate was a way for Moderna to improve its chances of the vaccine meeting efficacy targets during the first round of trials. But thanks to Pfizer’s shot and Moderna’s own trials, the company now knows that it can achieve the same results with less vaccine.

Smaller vaccine dose: Moderna is currently trialing versions of its vaccine that have been tweaked to protect against specific variants of the coronavirus, administering them as both stand-alone vaccines and boosters for people who received the company’s initial shot.

These trials include doses half as large as the one currently authorized in the U.S., and Moderna is already making deals with manufacturers to produce doses of that size.

“We’re assuming that as of 2022, we are going to have a mix of dose levels on the market,” a Moderna spokesperson told Reuters.

It’s not unheard of to have different doses of a vaccine. The flu shot has a high-dose formulation, with four times the regular dose, which is available to older people whose immune systems don’t respond as strongly to the standard flu shot.

There’s a long history of second-gen vaccines being multiply improved over first-gen vaccines.


Scot Roberts

Why it matters: Smaller doses of the Moderna COVID-19 vaccine should mean fewer side effects, which could help decrease vaccine hesitancy, at least in the U.S., where side effects are a primary reason people give for passing on the shot.

The switch would also mean doubling the number available doses, since the same amount of vaccine could be used for twice as many shots.

The bottom line: The currently authorized vaccines have already proven to be game-changers in the battle against COVID-19, but expect Moderna and other developers to continue to improve upon their initial creations.

“There’s a long history within vaccinology of second-generation vaccines being multiply improved over first-generation vaccines,” Scot Roberts, CSO of biotech company Altimmune, told USA Today. “That’s just the way things go.”

We’d love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at [email protected].

Related
This “living medicine” can eliminate a deadly lung infection
Researchers have engineered bacteria to create a “living medicine” against a nasty respiratory bug.
New mRNA vaccine factory is made from shipping containers
BioNTech is sending a modular mRNA vaccine factory that can produce 50 million COVID-19 vaccines annually to Africa.
Moderna’s RSV vaccine over 80% effective in early analysis
Moderna’s mRNA RSV vaccine for adults looks to be over 80% effective, based on early data from a large phase 3 trial.
Stanford nasal study could lead to “morning after” virus spray
A “morning after” antiviral nasal spray could be created using new knowledge about how SARS-CoV-2 invades your nose.
New mRNA universal flu vaccine against all known subtypes takes promising first steps
A new universal flu vaccine candidate that uses mRNA to target all known flu subtypes looks promising in animal models.
Up Next
Valley fever vaccine
Subscribe to Freethink for more great stories